Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer.

Rahul Aggarwal,Joshi J Alumkal,Russell Z Szmulewitz,Celestia S Higano,Alan H Bryce,Angela Lopez-Gitlitz,Sharon A McCarthy,Branko Miladinovic,Kelly McQuarrie,Shibu Thomas,Ke Zhang,Eric J Small

Prostate cancer（2022）

引用 1|浏览16

暂无评分

摘要

HRQoL was similar in patients treated with apalutamide alone, ADT alone, or their combination, although apalutamide plus ADT did not demonstrate statistically significant noninferiority in change from baseline in overall HRQoL. The aggregated efficacy and safety outcomes support further evaluation of apalutamide plus ADT in BCR PC.

查看译文

关键词

androgen deprivation monotherapy,androgen deprivation therapy,apalutamide monotherapy,prostate cancer,open-label

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要